2-乙氧基-5-嘧啶胺 | 73418-86-7

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-乙氧基-5-嘧啶胺
• 英文名称: 5-Amino-2-ethoxy-pyrimidin
• 英文别名: 2-ethoxy-pyrimidin-5-ylamine；2-Ethoxypyrimidin-5-amine
• CAS: 73418-86-7
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: KPNZINMQYGYLCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-乙氧基-5-嘧啶胺 在 溶剂黄146 、 肼 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 6-(2-Ethoxypyrimidin-5-yl)-1,4,5,7-tetramethylpyrrolo[3,4-d]pyridazine
  参考文献：
  名称：

  Synthesis and biological evaluation of 6-aryl-6 H -pyrrolo[3,4- d ]pyridazine derivatives as high-affinity ligands of the α 2 δ subunit of voltage-gated calcium channels

  摘要：

  A novel class of 2H-pyrrolo[3,4-c]pyridazine ligands of the alpha(2)delta subunit of voltage-gated calcium channels is described. Compound 4a with high affinity toward alpha(2)delta was identified through structure-activity relationship studies of the lead compound. Tritiated ligand [H-3]-4b was synthesized to demonstrate that this ligand binds to the same site as Gabapentin toward alpha(2)delta subunit of voltage-gated calcium channels. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.070

文献信息

• [EN] HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] COMPOSÉS HÉTÉROARYLE POUVANT ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：UNIV COLLEGE CARDIFF CONSULTANTS LTD

  公开号：WO2022234271A1

  公开（公告）日：2022-11-10

  The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAAreceptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAAreceptors, including depression and cognitive impairment, for example, congintive impairment associated with a psychotic disorder such as schizophrenia.

  本发明提供了式（I）的化合物，以及其药学上可接受的盐：其中X1，X2，X3，R3，环A和环B如本文所述。该化合物具有与α5亚单位含量的GABAA受体的亲和力。本发明进一步提供了制备式（I）化合物的方法，包括含有该化合物的药物组合物以及将其用作治疗与α5-GABAA受体相关的疾病和障碍的药物，包括抑郁症和认知障碍，例如与精神疾患如精神分裂症相关的认知障碍。
• Verbindungen als Bradykinin-B1-Antagonisten
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2401256B1

  公开（公告）日：2013-04-17
• N-PYRROLIDINYL, N'-PYRAZOLYL- UREA COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP3409670B1

  公开（公告）日：2020-09-09
• Malononitrile Compounds for Controlling Animal Pests
  申请人：BASF SE

  公开号：US20190104733A1

  公开（公告）日：2019-04-11

  The invention relates to the use of a compound of formula (I) or a salt thereof for combating animal pests, where the symbols and indices are defined in the specification.
• [EN] C-TERMINAL SRC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SRC C-TERMINALE
  申请人：INVENTISBIO SHANGHAI LTD

  公开号：WO2020124397A1

  公开（公告）日：2020-06-25

  Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e. g., having Formula (G), (I), (II), or (III). Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof.